Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
Código da empresaLNTH
Nome da EmpresaLantheus Holdings Inc
Data de listagemJun 25, 2015
CEOMarkison (Brian A)
Número de funcionários808
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 25
Endereço331 Treble Cove Road
CidadeNORTH BILLERICA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal01862
Telefone19786718001
Sitehttps://www.lantheus.com/
Código da empresaLNTH
Data de listagemJun 25, 2015
CEOMarkison (Brian A)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados